Letters to the Editor

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Hospital Universitario de Salamanca, Spain; University of Salamanca
University Hospital Hamburg-Eppendorf, Hamburgo
National and Kapodistrian University of Athens, Medicine School, Athens, Greece
Evangelismos General Hospital, Athens, Greece
National and Kapodistrian University of Athens, Medicine School, Athens, Greece
University of Bologna
University Hospital Leuven, Leuven
Hospital Universitario Marques de Valdecilla (IDIVAL), Santander, Spain; University of Cantabria, Santander, Spain
Theageneion Cancer Hospital, Thessaloniki, Greece
University of Torino, Italy; AOU Citta della Salute e della Scienza of Turin
University of Torino, Italy; AOU Citta della Salute e della Scienza of Turin
Hopital La Mileterie
Clinica Universidad de Navarra, Pamplona. Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona. Spain; Instituto de Investigacion Sanitaria de Navarra IDISNA, Pamplona. Spain; Centro de Investigacion Biomedica en Red en Cancer (CIBERONC) Pamplona, Spain
Oslo Myeloma Center, Oslo, Norway; Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”, Bologna, Italy; Universita di Bologna, Bologna
National and Kapodistrian University of Athens, Medicine School, Athens, Greece
Haematologica Early view Feb 22, 2024 https://doi.org/10.3324/haematol.2023.284694